 SAN DIEGO , April 5, 2022 PRNewswire -- Inhibrx, Inc. Nasdaq: INBX, a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that late-breaking data from INBRX-101 will be presented at the American Thoracic Society ATS 2022 Conference to be held May 13 th- 18th, 2022 in San Francisco, CA. Details on the oral presentation are shared below: Title: INBRX-101: A Novel Recombinant AAT-Fc Fusion Protein That Achieves Normal Serum AAT Levels with Extended Interval Dosing for Patients with Alpha-1 Antitrypsin Deficiency Session: Late Breaking Mini Symposium. 